patient subgroup...
age >= 55 yr age >= 65 yr critical disease
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
convalescent plasma treatment - versus control - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.99 [0.93, 1.05]< 1 0% 24 studies (24/-) 63.9 % some concern critical moderate crucial - deaths 0.98 [0.92, 1.04]< 1 0% 37 studies (37/-) 77.4 % some concern critical moderate crucial 1 deaths (time to event analysis only) 0.99 [0.79, 1.24]< 1 0% 7 studies (7/-) 54.7 % some concern not evaluable moderate crucial - clinical deterioration 0.87 [0.71, 1.06]< 1 9% 5 studies (5/-) 91.7 % some concern not evaluable moderate important - clinical improvement 1.09 [0.87, 1.38]> 1 39% 8 studies (8/-) 77.9 % some concern not evaluable moderate important - clinical improvement (14-day) 2.27 [0.90, 5.72]> 1 0% 1 study (1/-) 95.9 % NA not evaluable important - clinical improvement (28-day) 1.33 [0.83, 2.14]> 1 53% 5 studies (5/-) 88.1 % some concern not evaluable moderate important - clinical improvement (7-day) 0.98 [0.27, 3.58]> 1 0% 1 study (1/-) 48.8 % NA not evaluable important - clinical improvement (time to event analysis only) 1.08 [0.90, 1.29]> 1 0% 5 studies (5/-) 80.5 % low not evaluable high important - death or ventilation 0.98 [0.94, 1.03]< 1 0% 5 studies (5/-) 79.2 % some concern not evaluable moderate important - hospital discharge 1.00 [0.94, 1.07]> 1 0% 3 studies (3/-) 52.3 % some concern not evaluable moderate important - mechanical ventilation 0.83 [0.64, 1.08]< 1 24% 7 studies (7/-) 91.7 % some concern not evaluable moderate important 1 mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 1 0% 2 studies (2/-) 55.5 % some concern not evaluable moderate important - viral clearance 1.10 [0.19, 6.30]> 1 0% 2 studies (2/-) 54.1 % some concern not evaluable moderate important - viral clearance by day 14 0.96 [0.77, 1.20]> 1 0% 2 studies (2/-) 35.7 % some concern not evaluable moderate important - viral clearance by day 7 0.87 [0.65, 1.16]> 1 0% 2 studies (2/-) 17.4 % some concern not evaluable moderate important - ICU admission 0.67 [0.32, 1.41]< 1 1% 2 studies (2/-) 85.6 % some concern not evaluable moderate non important - 00 serious adverse events 1.19 [0.94, 1.50]< 1 45% 6 studies (6/-) 7.8 % some concern not evaluable moderate important - adverse events 1.08 [0.86, 1.37]< 1 0% 2 studies (2/-) 24.8 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
